MedTrace Logo

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration

NCT05953012 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2025-12-30

No results posted yet for this study

Summary

This is a Phase 1 study, first-in-human (FIH), open label study to evaluate the safety, tolerability and identify the maximum tolerated dose (MTD) of PMC-403 and determine the recommended phase 2 dose (RP2D).

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

PMC-403

PMC-403 will be administered Intravitreal.

Sponsors & Collaborators

  • C&R Research, Inc.

    collaborator INDUSTRY

  • PharmAbcine

    lead INDUSTRY

Principal Investigators

  • SeJoon Woo · Seoul National University Bundang Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-20
Primary Completion
2025-08-22
Completion
2025-12-17

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05953012 on ClinicalTrials.gov